ATE550429T1 - Adenovirus-zusammensetzungen erhältlich durch ein verbessertes produktions- und reinigungsverfahren - Google Patents

Adenovirus-zusammensetzungen erhältlich durch ein verbessertes produktions- und reinigungsverfahren

Info

Publication number
ATE550429T1
ATE550429T1 AT06025694T AT06025694T ATE550429T1 AT E550429 T1 ATE550429 T1 AT E550429T1 AT 06025694 T AT06025694 T AT 06025694T AT 06025694 T AT06025694 T AT 06025694T AT E550429 T1 ATE550429 T1 AT E550429T1
Authority
AT
Austria
Prior art keywords
yields
serum
purification process
improved production
improved
Prior art date
Application number
AT06025694T
Other languages
English (en)
Inventor
Shuyuan Zhang
Capucine Twin
Zheng Wu
Toohyoon Cho
Lucetta Caston
Deborah Wilson
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21858843&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE550429(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Application granted granted Critical
Publication of ATE550429T1 publication Critical patent/ATE550429T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cleaning And De-Greasing Of Metallic Materials By Chemical Methods (AREA)
  • Multi-Process Working Machines And Systems (AREA)
  • Saccharide Compounds (AREA)
AT06025694T 1996-11-20 1997-11-20 Adenovirus-zusammensetzungen erhältlich durch ein verbessertes produktions- und reinigungsverfahren ATE550429T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3132996P 1996-11-20 1996-11-20

Publications (1)

Publication Number Publication Date
ATE550429T1 true ATE550429T1 (de) 2012-04-15

Family

ID=21858843

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06025694T ATE550429T1 (de) 1996-11-20 1997-11-20 Adenovirus-zusammensetzungen erhältlich durch ein verbessertes produktions- und reinigungsverfahren
AT97950677T ATE348155T1 (de) 1996-11-20 1997-11-20 Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT97950677T ATE348155T1 (de) 1996-11-20 1997-11-20 Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren

Country Status (15)

Country Link
US (7) US6194191B1 (de)
EP (3) EP0968284B1 (de)
JP (1) JP4492826B2 (de)
KR (1) KR100503701B1 (de)
CN (1) CN1244215B (de)
AT (2) ATE550429T1 (de)
AU (1) AU732703B2 (de)
BR (1) BR9713368A (de)
CA (1) CA2272820C (de)
DE (1) DE69737107T2 (de)
ES (2) ES2278399T3 (de)
HK (1) HK1107116A1 (de)
NO (1) NO992389L (de)
NZ (1) NZ335947A (de)
WO (1) WO1998022588A2 (de)

Families Citing this family (256)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0847442A1 (de) * 1995-08-30 1998-06-17 Genzyme Corporation Chromatographische reinigung von adenoviren und aav
US20020088014A1 (en) * 1996-05-31 2002-07-04 Xiangming Fang Minimal adenovirus mediated recombinant vaccine
IL127692A0 (en) 1996-07-01 1999-10-28 Rhone Poulenc Rorer Sa Method for producing recombinant adenovirus
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
KR100503701B1 (ko) * 1996-11-20 2005-07-26 인트로겐 테라페티스, 인코퍼레이티드 아데노바이러스 벡터를 생산하고 정제하는 개선된 방법
US6544769B1 (en) 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
US6995006B2 (en) * 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
JP4303418B2 (ja) * 1997-10-24 2009-07-29 ライフ テクノロジーズ コーポレーション 組換え部位を有する核酸を使用する組換えクローニング
US7705602B2 (en) * 1997-11-03 2010-04-27 Midtronics, Inc. Automotive vehicle electrical system diagnostic device
US20040204381A1 (en) * 1997-11-12 2004-10-14 Moskal Joseph R Detection and treatment of glyco-enzyme-related disease
US6899870B1 (en) * 1998-03-11 2005-05-31 Board Of Regents, The University Of Texas System Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery
AU756889B2 (en) * 1998-04-22 2003-01-23 Genvec, Inc. Efficient purification of adenovirus
WO2000022152A1 (en) * 1998-10-13 2000-04-20 Avigen, Inc. Compositions and methods for producing recombinant adeno-associated virus
US7691370B2 (en) * 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
EP1133316B1 (de) * 1998-11-16 2009-01-21 Introgen Therapeutics, Inc. Adenovirus-formulierungen zur gentherapie
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US7148035B1 (en) * 1998-11-18 2006-12-12 Oxford Biomedica (Uk) Limited Polypeptide
US6210922B1 (en) * 1998-11-30 2001-04-03 National Research Council Of Canada Serum free production of recombinant proteins and adenoviral vectors
FR2788064B1 (fr) * 1998-12-31 2003-01-31 Aventis Pharma Sa Methode de separation de particules virales
CZ20012428A3 (cs) * 1998-12-31 2001-11-14 Aventis Pharma S. A. Způsob separace virových částic
DE60029195T2 (de) 1999-02-22 2007-06-28 Transgene S.A. Verfahren zur Gewinnung von purifizierter Virenzusammensetzung
US6795585B1 (en) 1999-07-16 2004-09-21 Eastman Kodak Company Representing digital images in a plurality of image processing states
CA2395820A1 (en) * 1999-12-29 2001-07-05 Genzyme Corporation Method using filtration aids for the separation of virus vectors from nucleic acids and other cellular contaminants
US6168941B1 (en) * 2000-04-07 2001-01-02 Genvec, Inc. Method of producing adenoviral vector stocks
JP2004509065A (ja) * 2000-04-28 2004-03-25 ゼンジェン　インコーポレイテッド α−ＭＳＨおよびその誘導体を用いる遺伝子治療システムおよび方法
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
TWI289158B (en) * 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US20020064860A1 (en) * 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
BR0207527A (pt) * 2001-03-16 2004-02-25 Oncolytics Biotech Inc Método para produzir vìrus de uma cultura de células, composição, e, método para produzir reovìrus infeccioso
US20040146590A1 (en) 2001-03-22 2004-07-29 Iadarola Michael J Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin
ES2328466T3 (es) * 2001-03-27 2009-11-13 Vertex Pharmaceuticals Incorporated Composiciones y metodos utiles para la infeccion por hcv.
WO2003014367A1 (en) 2001-08-08 2003-02-20 The Trustees Of The University Of Pennsylvania Method for purification of viral vectors having proteins which bind sialic acid
AU2002332736A1 (en) * 2001-08-30 2003-03-18 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of New adenovirus type 7 vectors
EP1432791B2 (de) * 2001-09-06 2013-10-23 Alphavax, Inc. Alphavirus replikon-vektorsysteme
AU2002348151A1 (en) * 2001-11-05 2003-05-19 Genvec, Inc. Viral vector production methods and compositions
SI1407006T1 (sl) * 2001-12-20 2006-04-30 Bavarian Nordic As Postopek za ponovno pridobivanje in ciscenje poksvirusov iz inficiranih celic
KR100451308B1 (ko) * 2001-12-28 2004-10-06 선바이오(주) 단백질 의약품 정제 방법에서의 바이러스 제거 방법
WO2003068933A2 (en) * 2002-02-14 2003-08-21 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
US7316898B2 (en) * 2002-02-20 2008-01-08 Merck & Co., Inc. Method of determining adenovirus particle concentration
US20030180936A1 (en) * 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
US20030175688A1 (en) * 2002-03-15 2003-09-18 Rukmini Pennathur-Das Method for the purification and production of oncolytic adenoviruses
US20030186832A1 (en) * 2002-03-15 2003-10-02 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Isotropic liquid detergents with improved anti-redeposition
CA2478932A1 (en) * 2002-03-29 2003-10-16 Merck & Co., Inc. Large scale methods of producing adenovirus and adenovirus seed stocks
AU2003229159B2 (en) 2002-04-30 2008-02-21 Oncolytics Biotech Inc. Improved viral purification methods
ES2357366T3 (es) 2002-05-14 2011-04-25 MERCK SHARP & DOHME CORP. Procedimientos de purificación de adenovirus.
US20030224354A1 (en) * 2002-05-30 2003-12-04 Introgen Therapeutics Inc. Quantifying viral particles with intrinsic fluorescence
EP1371723A1 (de) * 2002-06-12 2003-12-17 Procorde GmbH Verfahren zur Herstellung von einer Adenoviruszubereitung
WO2004009768A2 (en) * 2002-07-18 2004-01-29 Invitrogen Corporation Viral vectors containing recombination sites
AU2003268210A1 (en) * 2002-08-28 2004-03-19 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
JP4560483B2 (ja) * 2002-10-03 2010-10-13 ターゲジェン インコーポレーティッド 血管静態化物質およびそれらの使用法
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
AU2003298594A1 (en) * 2002-11-01 2004-06-07 Promega Corporation Cell lysis compositions, methods of use, apparatus, and kit
AU2003297041B2 (en) * 2002-12-13 2009-02-26 Alphavax, Inc. Alphavirus particles and methods for preparation
WO2004055166A2 (en) * 2002-12-13 2004-07-01 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
WO2004064785A2 (en) 2003-01-14 2004-08-05 Dana Farber Cancer Institute Cancer therapy sensitizer
CN1791678A (zh) * 2003-03-20 2006-06-21 阿尔法瓦克斯公司 改进的甲病毒复制子和辅助构建体
JP2006525015A (ja) * 2003-05-01 2006-11-09 ディーエスエム アイピー アセッツ ビー．ブイ． 懸濁した動物細胞の灌流培養による生物学的物質の製造方法
US20040229335A1 (en) * 2003-05-15 2004-11-18 Introgen Therapeutics, Inc. Methods and compositions for the production of adenoviral vectors
CN1816619A (zh) * 2003-06-18 2006-08-09 昂尼克斯药物公司 纯化病毒的方法
WO2005007689A1 (en) * 2003-07-11 2005-01-27 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines
AU2004263274B2 (en) 2003-07-21 2009-11-05 Transgene S.A. Novel multifunctional cytokines
EP1697534B1 (de) * 2003-12-01 2010-06-02 Life Technologies Corporation Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
EP1697505A1 (de) * 2003-12-23 2006-09-06 Schering Corporation Methoden zur herstellung von a549 zelllinien, die in serumfreiem medium in suspensionskultur stabil sind
AU2005214090B2 (en) * 2004-02-23 2008-09-11 Crucell Holland B.V. Virus purification methods
CN100333797C (zh) * 2005-01-26 2007-08-29 彭朝晖 重组腺病毒p53制品在肿瘤治疗中的新用途
NZ588139A (en) * 2004-04-08 2012-02-24 Targegen Inc 7-Aryl-3-arylamino-benzo[1,2,4]triazine derivatives
AU2005245956B2 (en) * 2004-05-18 2011-05-19 Alphavax, Inc. TC-83-derived alphavirus vectors, particles and methods
JP2008501339A (ja) * 2004-06-01 2008-01-24 ジェンザイム・コーポレイション Ａａｖベクターの凝集を防ぐための組成物およびその方法
US20050287616A1 (en) * 2004-06-29 2005-12-29 Gross Adam F Method of assaying denaturation of proteins
MX2007002208A (es) 2004-08-25 2007-05-08 Targegen Inc Compuestos hetrociclicos y metodos de uso.
DE202004014949U1 (de) * 2004-09-25 2004-11-18 Techno-Grafica Gmbh Vorrichtung zum Wärmebehandeln einer Beschichtung von Flachoffset-Druckplatten
DE102004049290A1 (de) * 2004-10-09 2006-04-20 Bayer Healthcare Ag Verfahren zur Herstellung von Virusmaterial
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
CA2586107A1 (en) * 2004-11-03 2006-05-18 Introgen Therapeutics Inc. A novel method for the production and purification of adenoviral vectors
CN100497640C (zh) * 2004-11-26 2009-06-10 中国人民解放军军事医学科学院生物工程研究所 一种高效生产重组腺病毒载体的方法
US20060166364A1 (en) * 2004-12-22 2006-07-27 Introgen, Inc. Use of flexible bag containers for viral production
EP1831353B1 (de) 2004-12-23 2012-02-29 MedImmune, LLC Nichttumorbildende mdck-zellinie zur vermehrung von viren
US20060205080A1 (en) * 2005-03-01 2006-09-14 David Frey Formulations for therapeutic viruses having enhanced storage stability
ES2716874T3 (es) 2005-03-23 2019-06-17 Genmab As Anticuerpos contra cd38 para el tratamiento del mieloma múltiple
CN101155915B (zh) * 2005-04-11 2013-12-04 克鲁塞尔荷兰公司 利用超滤进行病毒纯化
CA2912012C (en) * 2005-05-05 2018-05-29 Sensient Flavors Inc. Production of beta-glucans and mannans
AU2006254825A1 (en) * 2005-06-08 2006-12-14 Targegen, Inc. Methods and compositions for the treatment of ocular disorders
US20090216452A1 (en) * 2005-07-05 2009-08-27 Develop Tech Resources Energy recovery within a fluid distribution network using geographic information
PT1951684T (pt) 2005-11-01 2016-10-13 Targegen Inc Inibidores de cinases de tipo biaril-meta-pirimidina
US8133900B2 (en) * 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
DE602007009954D1 (de) * 2006-03-22 2010-12-02 Viral Logic Systems Technology Verfahren zur identifizierung von polypeptid-targets
WO2007127366A2 (en) * 2006-04-25 2007-11-08 Targegen, Inc. Kinase inhibitors and methods of use thereof
WO2008105931A2 (en) 2006-09-15 2008-09-04 Medimmune Vaccines, Inc. Mdck cell lines supporting viral growth to high titers and bioreactor process using the same
CN101617052A (zh) 2007-01-30 2009-12-30 特兰斯吉恩股份有限公司 用于免疫的***瘤病毒e2多肽
US20080299624A1 (en) * 2007-06-01 2008-12-04 Edward Heslop Continuous fermentation apparatus and method
PL2947149T3 (pl) * 2007-06-21 2018-09-28 Alphavax, Inc. Kasety bez promotora do ekspresji alfawirusowych białek strukturalnych
KR101655487B1 (ko) * 2007-10-08 2016-09-08 인트렉손 코포레이션 가공된 수지상 세포 및 암의 치료를 위한 이의 용도
EP2612868B1 (de) 2007-11-01 2018-08-15 Astellas Pharma Inc. Immunsuppressive Polypeptide und Nucleinsäuren
US20090253184A1 (en) * 2008-01-23 2009-10-08 Introgen Therapeutics, Inc. Compositions and methods related to an adenoviral trans-complementing cell line
CA2723726C (en) 2008-05-13 2017-09-12 Michael M. Becker Inactivatable target capture oligomers for use in the selective hybridization and capture of target nucleic acid sequences
JP5615271B2 (ja) * 2008-06-18 2014-10-29 オックスフォード バイオメディカ（ユーケー）リミテッド ウイルス精製法
CN102215865B (zh) * 2008-09-24 2013-10-30 米迪缪尼有限公司 病毒纯化方法
CN102216450B (zh) * 2008-09-24 2014-05-14 米迪缪尼有限公司 培养细胞、增殖和纯化病毒的方法
ES2532015T3 (es) 2008-11-03 2015-03-23 Crucell Holland B.V. Método para la producción de vectores adenovíricos
US20110262483A1 (en) * 2008-11-03 2011-10-27 Ligocyte Pharmaceuticals, Inc. Methods for isolating enveloped virus-based vlps free of infectious agents
WO2010136979A2 (en) * 2009-05-26 2010-12-02 Leviathan Energy Hydroelectric Ltd. Hydroelectric in-pipe turbine uses
CN103331185A (zh) * 2009-07-07 2013-10-02 索尼公司 微流体装置
SG178254A1 (en) 2009-08-07 2012-03-29 Transgene Sa Composition for treating hbv infection
CN102575233B (zh) 2009-10-15 2014-07-16 克鲁塞尔荷兰公司 从高细胞密度培养物纯化腺病毒的方法
AU2010305765B2 (en) 2009-10-15 2015-07-02 Crucell Holland B.V. Method for the purification of adenovirus particles
EP3159405B8 (de) 2010-01-05 2018-11-07 Vascular Biogenics Ltd. Verfahren zur verwendung eines spezifischen adenovirenmittels gegen angiogenese
EP2521777B1 (de) 2010-01-05 2016-12-28 Vascular Biogenics Ltd. Zusammensetzungen und verfahren zur behandlung von glioblastomen (gbm)
WO2011086509A1 (en) * 2010-01-12 2011-07-21 Vascular Biogenics Ltd. Methods of producing adenovirus vectors and viral preparations generated thereby
WO2011098592A1 (en) 2010-02-15 2011-08-18 Crucell Holland B.V. Method for the production of ad26 adenoviral vectors
JP2013523175A (ja) * 2010-04-14 2013-06-17 イーエムディー・ミリポア・コーポレーション 高力価、高純度のウイルスストックの作製方法及びその使用方法
CN103052399B (zh) 2010-08-12 2016-06-29 依生生物制药控股有限公司 用于减少病毒组合物中dna杂质的方法
US8771709B2 (en) 2010-09-20 2014-07-08 Crucell Holland B.V. Therapeutic vaccination against active Tuberculosis
US9168292B2 (en) 2010-09-27 2015-10-27 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
US8892184B2 (en) 2010-10-18 2014-11-18 Siemens Medical Solutions Usa, Inc. Systems and methods for reducing interference in a dual modality imaging system
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
EP2461162A1 (de) 2010-12-03 2012-06-06 Texcell, . Verfahren zur Bestimmung des Titers von Viren durch Verwendung von infektiösen Standardsubstanzen
CA2819552C (en) 2010-12-09 2023-09-26 Institut Pasteur Mgmt-based method for obtaining high yield of recombinant protein expression
TWI575070B (zh) 2011-07-12 2017-03-21 傳斯堅公司 Ｈｂｖ聚合酶突變體
WO2013045668A2 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
TW201318637A (zh) 2011-09-29 2013-05-16 Transgene Sa 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（一）
EP2780034A1 (de) 2011-11-14 2014-09-24 Crucell Holland B.V. Heterologe prime-boost-impfung mit auf masernviren basierten impfstoffen
CN104379733B (zh) 2012-03-12 2016-01-20 克鲁塞尔荷兰公司 具改变末端的重组腺病毒群
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
MY169352A (en) 2012-03-22 2019-03-25 Janssen Vaccines & Prevention Bv Vaccine against rsv
SG11201500053RA (en) * 2012-07-26 2015-03-30 Vectalys Method for detecting or measuring the impact of a viral vector composition on eukaryotic cells and biomarkers used thereof
US9657076B2 (en) 2012-10-23 2017-05-23 Emory University GM-CSF and IL-4 conjugates, compositions, and methods related thereto
MX361774B (es) 2013-04-25 2018-12-17 Janssen Vaccines & Prevention Bv Polipéptidos f de prefusión del virus sincicial respiratorio (rsv) solubles y estabilizados.
EP2992553A4 (de) 2013-05-03 2017-03-08 Honeywell International Inc. Leiterrahmenkonstrukt für bleifreie lötverbindungen
PE20160045A1 (es) 2013-06-17 2016-02-18 Crucell Holland Bv Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados
US9956166B2 (en) 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
US20160257987A1 (en) * 2013-10-30 2016-09-08 Merck Patent Gmbh Method for isolating microorganisms from a complex sample
JP2017509489A (ja) 2014-02-20 2017-04-06 ハネウェル・インターナショナル・インコーポレーテッド 鉛フリーはんだ組成物
EP3613841B1 (de) 2014-03-25 2022-04-20 Terumo BCT, Inc. Passives ersetzen von medien
JP6571679B2 (ja) 2014-04-25 2019-09-04 トランスレイト バイオ， インコーポレイテッド メッセンジャーｒｎａの精製方法
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
CN105316296A (zh) * 2014-06-13 2016-02-10 亚宝药业太原制药有限公司 一种纯化腺病毒颗粒的方法
US20180133252A9 (en) 2014-09-09 2018-05-17 Unum Therapeutics Inc. Chimeric receptors and uses thereof in immune therapy
GB201417042D0 (en) 2014-09-29 2014-11-12 Fkd Therapies Oy Method
RU2020109343A (ru) 2014-11-05 2020-03-17 Вояджер Терапьютикс, Инк. Полинуклеотиды aadc для лечения болезни паркинсона
MX2017006216A (es) 2014-11-14 2018-08-29 Voyager Therapeutics Inc Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela).
DK3218386T3 (da) 2014-11-14 2021-06-07 Voyager Therapeutics Inc Modulatorisk polynukleotid
EP3230441A4 (de) 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Zusammensetzungen und verfahren zur herstellung von scaav
SG11201704919SA (en) * 2015-01-13 2017-07-28 Alfa Wassermann Inc Methods of purifying adeno-associated virus (aav) and/or recombinant adeno-associated virus (raav)
EP3054007A1 (de) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Reinigung von rekombinanten, adeno-assoziierten viren mit einem immunaffinen reinigungsschritt
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
US10570417B2 (en) 2015-04-14 2020-02-25 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
JP6840718B2 (ja) 2015-07-07 2021-03-10 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 安定化された可溶性融合前ｒｓｖ ｆポリペプチド
WO2017005844A1 (en) 2015-07-07 2017-01-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
US9663766B2 (en) * 2015-07-24 2017-05-30 Bio-Rad Laboratories, Inc. Methods for purifying adenovirus vectors
CA3001859A1 (en) 2015-10-16 2017-04-20 The Trustees Of Columbia University In The City Of New York Compositions and methods for inhibition of lineage specific antigens
EP3368054A4 (de) 2015-10-28 2019-07-03 Voyager Therapeutics, Inc. Regulierbare expression unter verwendung des adeno-assoziierten virus (aav)
BR112018070323A2 (pt) 2016-04-05 2019-01-29 Janssen Vaccines & Prevention Bv vacina contra rsv
AU2017248021B2 (en) 2016-04-05 2021-08-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F proteins
KR102535013B1 (ko) * 2016-04-14 2023-05-22 트리젤 엘티디. 정유량 펌프/튜빙 시스템이 있는 고정층 바이오 리액터
KR20230022177A (ko) * 2016-04-14 2023-02-14 트리젤 엘티디. 정유량 펌프/튜빙 시스템이 있는 고정층 바이오 리액터
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US20190134190A1 (en) 2016-05-04 2019-05-09 Transgene Sa Combination therapy with cpg tlr9 ligand
CN109831916B (zh) 2016-05-18 2023-07-21 沃雅戈治疗公司 治疗亨廷顿氏舞蹈病的组合物和方法
IL302748A (en) 2016-05-18 2023-07-01 Voyager Therapeutics Inc modulatory polynucleotides
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
WO2017207480A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11001858B2 (en) 2016-06-20 2021-05-11 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
WO2018011196A1 (en) 2016-07-14 2018-01-18 Janssen Vaccines & Prevention B.V. Hpv vaccines
EP3831281A1 (de) 2016-08-30 2021-06-09 The Regents of The University of California Verfahren für biomedizinisches targeting und freisetzung sowie vorrichtungen und systeme zur ausführung davon
EP3522920A2 (de) 2016-10-10 2019-08-14 Transgene SA Immuntherapeutisches produkt und mdsc-modulator-kombinationstherapie
WO2018080573A1 (en) 2016-10-28 2018-05-03 Massachusetts Institute Of Technology Crispr/cas global regulator screening platform
US10294452B2 (en) 2016-11-22 2019-05-21 Dao-Yao He Lysis, extraction and purification of adeno-associated virus and adenovirus from host cells
CN108085301B (zh) * 2016-11-22 2021-10-26 贺道耀 从宿主细胞提取和纯化腺相关病毒和腺病毒的方法及其组分和试剂盒
WO2018106888A1 (en) * 2016-12-08 2018-06-14 Temple University-Of The Commonwealth System Of Higher Education Small animal models for in vivo testing of polyomavirus therapeutics
WO2018148246A1 (en) 2017-02-07 2018-08-16 Massachusetts Institute Of Technology Methods and compositions for rna-guided genetic circuits
EP3656842A1 (de) 2017-03-31 2020-05-27 Terumo BCT, Inc. Zellexpansion
CN110913866A (zh) 2017-05-05 2020-03-24 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
US11752181B2 (en) 2017-05-05 2023-09-12 Voyager Therapeutics, Inc. Compositions and methods of treating Huntington's disease
EP3624844A1 (de) 2017-05-17 2020-03-25 Janssen Vaccines & Prevention B.V. Verfahren und zusammensetzungen zur induzierung schützender immunität gegen rsv-infektionen
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
WO2019018342A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. NETWORK EQUIPMENT TRACK GUIDE SYSTEM
EP3662060A2 (de) 2017-08-03 2020-06-10 Voyager Therapeutics, Inc. Zusammensetzungen und verfahren zur aav-freisetzung
CN107384873A (zh) * 2017-09-05 2017-11-24 成都汇宇生物技术有限公司 重组腺病毒的纯化方法
EP3681533A1 (de) 2017-09-15 2020-07-22 Janssen Vaccines & Prevention B.V. Verfahren zur sicheren induktion der immunität gegen rsv
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
JP7502991B2 (ja) 2017-10-16 2024-06-19 ボイジャー セラピューティクス インコーポレイテッド 筋萎縮性側索硬化症（ａｌｓ）の治療
WO2019092084A1 (en) * 2017-11-08 2019-05-16 Blue Sky Vaccines Gmbh So3 chromatography for use in a method for virus purification
EP3762500A1 (de) 2018-03-06 2021-01-13 Voyager Therapeutics, Inc. Aus insektenzelle hergestellte teilweise selbstkomplementäre aav-genome
CA3097192A1 (en) 2018-04-27 2019-10-31 Voyager Therapeutics, Inc. Methods for measuring the potency of aadc viral vectors
CA3099306A1 (en) 2018-05-15 2019-11-21 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease
EP3793616A1 (de) 2018-05-15 2021-03-24 Voyager Therapeutics, Inc. Zusammensetzungen und verfahren zur aav-freisetzung
WO2019222444A2 (en) 2018-05-16 2019-11-21 Voyager Therapeutics, Inc. Directed evolution
WO2019222441A1 (en) 2018-05-16 2019-11-21 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
JP2021529513A (ja) 2018-07-02 2021-11-04 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 筋萎縮性側索硬化症および脊髄に関連する障害の治療
CN112638402A (zh) 2018-07-03 2021-04-09 Sotio有限责任公司 与增强葡萄糖输入的反式代谢分子组合的嵌合受体及其治疗用途
US20210355454A1 (en) 2018-07-24 2021-11-18 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations
CN113423725A (zh) 2018-08-28 2021-09-21 Vor生物制药股份有限公司 遗传工程化造血干细胞及其用途
CA3115217A1 (en) 2018-10-02 2020-04-09 Voyager Therapeutics, Inc. Redirection of tropism of aav capsids
TW202035689A (zh) 2018-10-04 2020-10-01 美商航海家醫療公司 測量病毒載體粒子的效價及強度之方法
WO2020077165A1 (en) 2018-10-12 2020-04-16 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
WO2020123524A1 (en) * 2018-12-11 2020-06-18 Erbi Biosystems, Inc. Methods of manufacturing cell based products using small volume perfusion processes
AU2020208467A1 (en) 2019-01-18 2021-08-05 Voyager Therapeutics, Inc. Methods and systems for producing AAV particles
CN113710810A (zh) 2019-02-21 2021-11-26 安利舒免疫溶瘤技术公司 溶瘤腺病毒载体和使用方法
CN110093455B (zh) * 2019-04-27 2020-03-17 中国医学科学院病原生物学研究所 一种呼吸道病毒的检测方法
TW202106879A (zh) 2019-04-29 2021-02-16 美商航海家醫療公司 於生物反應器中生產經桿狀病毒感染之昆蟲細胞(biic)之系統及方法
WO2020227515A1 (en) 2019-05-07 2020-11-12 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
CN112175996A (zh) * 2019-07-05 2021-01-05 杭州荣泽生物科技有限公司 一种基因治疗载体的制备方法和用途
WO2021030125A1 (en) 2019-08-09 2021-02-18 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
WO2021041485A1 (en) 2019-08-26 2021-03-04 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2021046155A1 (en) 2019-09-03 2021-03-11 Voyager Therapeutics, Inc. Vectorized editing of nucleic acids to correct overt mutations
US20220389361A1 (en) * 2019-11-15 2022-12-08 City Of Hope System, device and method for production of bioproduct including high density cell respirator for intensified production of adeno-associated viruses
CN110894494B (zh) * 2019-11-22 2022-09-27 广西梧州制药（集团）股份有限公司 一种大规模高密度悬浮培养293细胞高产腺病毒的方法
EP4126910A1 (de) 2020-04-01 2023-02-08 Voyager Therapeutics, Inc. Umleitung des tropismus von aav-kapsiden
EP4135841A1 (de) 2020-04-15 2023-02-22 Voyager Therapeutics, Inc. Tau-bindende verbindungen
GB202005732D0 (en) 2020-04-20 2020-06-03 Synpromics Ltd Regulatory nucleic acid sequences
WO2021230987A1 (en) 2020-05-13 2021-11-18 Voyager Therapeutics, Inc. Redirection of tropism of aav capsids
EP4192514A1 (de) 2020-08-06 2023-06-14 Voyager Therapeutics, Inc. Zellkulturmedium zur verwendung bei der herstellung von gentherapieprodukten in bioreaktoren
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
CN112226418B (zh) * 2020-09-25 2022-07-08 阜外华中心血管病医院 重组腺相关病毒纯化方法
EP4225382A2 (de) 2020-10-07 2023-08-16 Asklepios Biopharmaceutical, Inc. Therapeutische adeno-assoziierte virusverabreichung von fkutin-verwandtem protein (fkrp) zur behandlung von dystroglycanopathie. erkrankungen mit gliedmassengürtel 21
CN112293394B (zh) * 2020-10-30 2022-11-25 海南德安欣有害生物防治科技有限公司 一种捕鼠装置及捕鼠方法
CA3196778A1 (en) 2020-11-02 2022-05-05 Biomarin Pharmaceutical, Inc. Process for enriching adeno-associated virus
GB202019454D0 (en) * 2020-12-10 2021-01-27 Chancellor Masters And Scholars Of The Univ Of Oxford Method for purifying virus
US20240141378A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
US20240141377A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
US20240189447A1 (en) 2021-04-16 2024-06-13 Asklepios Biopharmaceutical, Inc. Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response
WO2023034980A1 (en) 2021-09-03 2023-03-09 Bomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023034997A1 (en) 2021-09-03 2023-03-09 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023034990A1 (en) 2021-09-03 2023-03-09 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023034989A1 (en) 2021-09-03 2023-03-09 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023034996A1 (en) 2021-09-03 2023-03-09 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023034994A1 (en) 2021-09-03 2023-03-09 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
IL311712A (en) 2021-09-27 2024-05-01 Sotio Biotech Inc Chimeric polypeptide receptors combined with trans-metabolism compounds that divert glucose metabolites outside the glycolysis pathway and their medical uses
TW202334436A (zh) 2021-11-02 2023-09-01 美商航海家醫療公司 Ａａｖ衣殼變異體及其用途
AU2022388928A1 (en) 2021-11-16 2024-05-16 Sotio Biotech Inc. Treatment of myxoid/round cell liposarcoma patients
WO2023091948A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
CA3240342A1 (en) 2021-12-16 2023-06-22 Gopal SAPKOTA Targeted degradation of alpha-synuclein
WO2023147374A2 (en) 2022-01-25 2023-08-03 Voyager Therapeutics, Inc. Baculovirus expression system
TW202346599A (zh) 2022-02-08 2023-12-01 美商航海家醫療公司 Ａａｖ衣殼變異體及其用途
GB202201713D0 (en) 2022-02-10 2022-03-30 Univ Dundee An affinity directed phosphatase system for targeted protein dephosphorylation
CN115354033A (zh) * 2022-03-25 2022-11-18 上海碧博生物医药科技有限公司 一种细胞裂解液、细胞裂解方法及该方法在收获aav的应用
WO2023235791A1 (en) 2022-06-02 2023-12-07 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2024006741A1 (en) 2022-06-28 2024-01-04 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2024011112A1 (en) 2022-07-06 2024-01-11 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2024040208A1 (en) 2022-08-19 2024-02-22 Sotio Biotech Inc. Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof
WO2024040207A1 (en) 2022-08-19 2024-02-22 Sotio Biotech Inc. Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof
WO2024054983A1 (en) 2022-09-08 2024-03-14 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2024059739A1 (en) 2022-09-15 2024-03-21 Voyager Therapeutics, Inc. Tau binding compounds
WO2024064863A2 (en) 2022-09-22 2024-03-28 Biomarin Pharmaceutical Inc. Treatment of arrhythmogenic cardiomyopathy with aav gene therapy vectors
WO2024064856A1 (en) 2022-09-22 2024-03-28 Biomarin Pharmaceutical Inc. Treatment of cardiomyopathy with aav gene therapy vectors
CN117551624A (zh) * 2024-01-11 2024-02-13 深圳源兴基因技术有限公司 一种基于无血清悬浮扩增的高效回收腺病毒的方法

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US789244A (en) * 1902-10-01 1905-05-09 Hans Thormeyer Steam-turbine.
US824544A (en) * 1905-12-04 1906-06-26 George Hossege Pipe-hanger.
US4222743A (en) * 1978-07-20 1980-09-16 Wang Wei Kung Method and apparatus for detecting biological particles by fluorescent stain
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4539020A (en) * 1983-07-10 1985-09-03 Kawasaki Steel Corporation Methods for obtaining high-purity carbon monoxide
JPS6147187A (ja) 1984-08-10 1986-03-07 Chemo Sero Therapeut Res Inst 狂犬病ウイルスの精製方法
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5173418A (en) * 1985-05-10 1992-12-22 Benzon Pharma, A/S Production in Escherichia coli of extracellular Serratia spp. hydrolases
US5139941A (en) * 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5106841A (en) * 1986-05-13 1992-04-21 Chai-Tech Corporation Antiviral compositions and method for their use
EP0273085A1 (de) 1986-12-29 1988-07-06 IntraCel Corporation Verfahren zur Einführung fremder Nukleinsäuren in eukaryotische Zellen
US5591624A (en) * 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
JPH0761955B2 (ja) 1988-04-28 1995-07-05 国立予防衛生研究所長 凍結乾燥ａ型肝炎ワクチン
US5219752A (en) * 1988-05-25 1993-06-15 Teijin, Limited Process for continuously culturing adherent animal cells
AU5037390A (en) 1989-01-16 1990-08-13 Telefunken Fernseh Und Rundfunk Gmbh Compatible frequency-division multiplex television system
WO1990013808A1 (de) * 1989-05-01 1990-11-15 Byk Gulden Lomberg Chem Fab Reflexionsfluorimeter
WO1991009310A1 (en) 1989-12-12 1991-06-27 Lidak Pharmaceuticals Free fatty acid determination
IT1238231B (it) 1989-12-18 1993-07-12 Consiglio Nazionale Ricerche Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
NO312681B1 (no) 1990-08-24 2002-06-17 Univ California Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet
US6410010B1 (en) * 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
IT1248075B (it) 1991-06-18 1995-01-05 Sclavo Spa Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.
EP0552108B1 (de) 1992-01-17 1999-11-10 Lakowicz, Joseph R. Phasenmodulationsenergieübertragungsfluoroimmunassay
US5323008A (en) 1992-03-23 1994-06-21 Diatron Corporation Fluorometer detection system
DK0713397T3 (da) 1992-03-24 2003-03-31 United Cancer Res Inst Vaccine indeholdende levende virus
US5428011A (en) 1992-06-16 1995-06-27 Procyon Biopharma, Inc. Pharmaceutical preparations for inhibiting tumours associated with prostate adenocarcinoma
US5733720A (en) * 1992-06-18 1998-03-31 Washington University Genetically engineered cell lines for detecting infectious herpesvirus and methods therefor
WO1994002638A1 (en) * 1992-07-17 1994-02-03 Aprogenex, Inc. Free radical scavengers useful for reducing autofluorescence in fixed cells
EP0672137A1 (de) 1992-09-18 1995-09-20 CANJI, Inc. Gentherapie durch einen retroviralen vektor mit einem tumorunterdrückenden gen
US5733721A (en) 1992-11-20 1998-03-31 The Board Of Regents Of The University Of Oklahoma Cell analysis method using quantitative fluorescence image analysis
EP0682697A4 (de) 1993-01-29 1997-07-30 New Brunswick Scientific Co Methode und gerät zur verankerung und suspension von zellkulturen.
US5604096A (en) * 1993-03-04 1997-02-18 Schaeffer; Warren I. Fluorometric quantitation of mycoplasmas
US5994314A (en) 1993-04-07 1999-11-30 Inhale Therapeutic Systems, Inc. Compositions and methods for nucleic acid delivery to the lung
CA2139623A1 (en) 1993-05-06 1994-11-24 Baxter Diagnostics Inc. Human papillomavirus detection assay
US5421339A (en) 1993-05-12 1995-06-06 Board Of Regents, The University Of Texas System Diagnosis of dysplasia using laser induced fluoroescence
US6686200B1 (en) * 1993-08-31 2004-02-03 Uab Research Foundation Methods and compositions for the large scale production of recombinant adeno-associated virus
AU7971194A (en) 1993-10-12 1995-05-04 Chiron Corporation Methods for preserving recombinant viruses
TW442569B (en) 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
CA2181066A1 (en) * 1994-01-12 1995-07-20 Hitoshi Kotani Purification of retroviral vectors
HRP950097A2 (en) 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
US5498537A (en) * 1994-03-09 1996-03-12 Cellco, Inc. Serum-free production of packaged viral vector
AU2127395A (en) * 1994-03-22 1995-10-09 Rhone-Poulenc Rorer Pharmaceuticals Inc. Highly efficient production and isolation of viral particles
US5521083A (en) * 1994-05-13 1996-05-28 The Research Foundation Of State University Of New York Et Al. Large granular lymphocyte leukemia associated virus
AU3551195A (en) * 1994-09-23 1996-04-09 Somatix Therapy Corporation Chimeric adenovirus for gene delivery
US5552309A (en) * 1994-09-30 1996-09-03 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells
US6348343B2 (en) * 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
US5837520A (en) * 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
US5707618A (en) 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
US5744304A (en) * 1995-05-30 1998-04-28 Board Of Regents, The University Of Texas System Inflammation-induced expression of a recombinant gene
US5772888A (en) * 1995-07-27 1998-06-30 Massachusetts Institute Of Technology Separation and/or concentration of an analyte from a mixture using a two-phase aqueous micellar system
EP0841942B2 (de) * 1995-08-01 2007-12-12 Sanofi Pasteur Verfahren zur industriellen herstellung eines japanischen enkephalitis impfstoffes, und so erhaltener impfstoff
EP0847442A1 (de) 1995-08-30 1998-06-17 Genzyme Corporation Chromatographische reinigung von adenoviren und aav
AU722042B2 (en) 1995-11-30 2000-07-20 Board Of Regents, The University Of Texas System Methods and compositions for the diagnosis and treatment of cancer
US5910434A (en) * 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
AR006240A1 (es) * 1996-03-14 1999-08-11 Fuller H B Licensing Financ Adhesivo de fusion caliente que comprende interpolimeros, articulo no tejido que lo comprende, procedimiento de polimerizacion para preparlo y caja, envase, bandeja y libro unidos con dicho adhesivo
JPH09262099A (ja) * 1996-03-28 1997-10-07 Aisin Seiki Co Ltd フルオレセイン誘導体リン酸エステルによる核酸等の検出方法
IL127692A0 (en) 1996-07-01 1999-10-28 Rhone Poulenc Rorer Sa Method for producing recombinant adenovirus
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
KR100503701B1 (ko) 1996-11-20 2005-07-26 인트로겐 테라페티스, 인코퍼레이티드 아데노바이러스 벡터를 생산하고 정제하는 개선된 방법
ATE477320T1 (de) 1996-12-13 2010-08-15 Schering Corp Methoden zur virus-reinigung
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
US6168944B1 (en) 1997-01-31 2001-01-02 Schering Corporation Methods for cultivating cells and propagating viruses
CA2282683A1 (en) 1997-02-18 1998-08-20 Canji, Inc. Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
US6130313A (en) 1997-10-02 2000-10-10 Clontech Laboratories, Inc. Rapidly degrading GFP-fusion proteins
BR9908015A (pt) 1998-02-17 2001-04-24 Schering Corp Composições que compreendem vìrus e métodos para concentração de preparações de vìrus
US5922576A (en) 1998-02-27 1999-07-13 The John Hopkins University Simplified system for generating recombinant adenoviruses
KR20010034600A (ko) 1998-03-10 2001-04-25 엔. 레이 앤더슨 미생물의 검출 및 성상 확인
US6265151B1 (en) * 1998-03-27 2001-07-24 Seroptix, Inc. Apparatus and method for infectious disease detection
AU756889B2 (en) 1998-04-22 2003-01-23 Genvec, Inc. Efficient purification of adenovirus
US6171790B1 (en) 1998-05-01 2001-01-09 Incyte Pharmaceuticals, Inc. Human protease associated proteins
WO1999060371A2 (en) 1998-05-15 1999-11-25 Geron Corporation Method and apparatus for detecting hazardous agents
JP3718430B2 (ja) 1998-06-30 2005-11-24 ラミナ，インコーポレイテッド 細胞および組織固定剤組成物および使用方法
EP1102976A1 (de) 1998-08-08 2001-05-30 Imperial Cancer Research Technology Limited Mehrfrequenz-fluoreszenzlebensdauer-abbildungsverfahren
US5965358A (en) 1998-08-26 1999-10-12 Genvec, Inc. Method for assessing the relative purity of viral gene transfer vector stocks
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
CZ20012428A3 (cs) 1998-12-31 2001-11-14 Aventis Pharma S. A. Způsob separace virových částic
US6316185B1 (en) * 1999-09-29 2001-11-13 Mountain View Pharmaceuticals, Inc. Quantitation of viruses by light scattering
JP2002054561A (ja) 2000-08-08 2002-02-20 Toyota Industries Corp 容量可変型圧縮機の制御弁及び容量可変型圧縮機
US6447995B1 (en) 2000-10-04 2002-09-10 Genvec, Inc. Utilizing intrinsic fluorescence to detect adenovirus
DE10050114A1 (de) * 2000-10-09 2002-04-25 Wolf Gmbh Richard Verwendung einer Gelmasse
AU2003268210A1 (en) * 2002-08-28 2004-03-19 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
US20040229335A1 (en) * 2003-05-15 2004-11-18 Introgen Therapeutics, Inc. Methods and compositions for the production of adenoviral vectors

Also Published As

Publication number Publication date
DE69737107D1 (de) 2007-01-25
AU732703B2 (en) 2001-04-26
US7445930B2 (en) 2008-11-04
EP0968284A2 (de) 2000-01-05
NZ335947A (en) 2000-12-22
KR20000057160A (ko) 2000-09-15
AU5361798A (en) 1998-06-10
US6194191B1 (en) 2001-02-27
JP4492826B2 (ja) 2010-06-30
NO992389L (no) 1999-07-19
WO1998022588A2 (en) 1998-05-28
CN1244215A (zh) 2000-02-09
EP1760151A1 (de) 2007-03-07
EP1707631A2 (de) 2006-10-04
HK1107116A1 (en) 2008-03-28
DE69737107T2 (de) 2007-07-12
ATE348155T1 (de) 2007-01-15
NO992389D0 (no) 1999-05-19
BR9713368A (pt) 2001-09-18
US20050089999A1 (en) 2005-04-28
WO1998022588A3 (en) 1998-10-15
EP0968284B1 (de) 2006-12-13
EP1707631A3 (de) 2006-12-27
CA2272820A1 (en) 1998-05-28
JP2001504701A (ja) 2001-04-10
US7510875B2 (en) 2009-03-31
EP1760151B1 (de) 2012-03-21
ES2383640T3 (es) 2012-06-25
CA2272820C (en) 2012-09-11
US6726907B1 (en) 2004-04-27
ES2278399T3 (es) 2007-08-01
US20100055763A1 (en) 2010-03-04
KR100503701B1 (ko) 2005-07-26
US20030008375A1 (en) 2003-01-09
US20020177215A1 (en) 2002-11-28
US20070155008A1 (en) 2007-07-05
CN1244215B (zh) 2010-11-03

Similar Documents

Publication Publication Date Title
ATE550429T1 (de) Adenovirus-zusammensetzungen erhältlich durch ein verbessertes produktions- und reinigungsverfahren
ATE452183T1 (de) Eine verbesserte methode zur herstellung und reinigung von adenoviralen vektoren
DK0733103T3 (da) Fremstilling af höje titre af rekombinante AAV vektorer
DE69633572D1 (de) Hilfsfunktionen fuer die rekombinante aav-virionherstellung
PT1064393E (pt) Composicoes e metodos para a producao de virus adeno-associados recombinantes sem auxiliar
ATE349542T1 (de) Zusammensetzungen und verfahren zur herstellung von helfer-freien rekombinanten adeno- assoziierten viren
CA2415990A1 (en) Method for producing biologicals in protein-free culture
ATE189697T1 (de) Die hocheffiziente herstellung und isolierung von viruspartikeln
WO2001036623A3 (en) Ecdysone-inducible adeno-associated virus expression vectors
WO2000014205A3 (en) Methods for generating high titer helper-free preparations of released recombinant aav vectors
ATE454039T1 (de) Verfharen zur herstellung von herpes-simplex- virus-amplikons, die resultierenden amplikons und ihre verwendung
WO1994013812A3 (en) Novel entomopoxvirus genes, proteins and methods of use thereof
HK1038572A1 (en) Growth differentiation factor promoter and uses therefor
EA199900101A1 (ru) Очищенные белки, последовательности рекомбинантной днк и способы управления созреванием растений кофе
DK326289D0 (da) Fremgangsmaade til fremstilling af et protein ud fra gaersvampe under anvendelse af et inducerbart system, samt vektorer og transformerede stammer til brug ved fremgangsmaaden
CO4480040A1 (es) Proceso de purificacion del antigeno de superficie viral hepatitis b que comprende el peptido pres 2
WO2000028039A3 (en) Identification of senv genotypes
CA2289776A1 (en) An infectious clone for human parainfluenza virus type 3
WO1992014818A3 (en) Entomopoxvirus expression system comprising spheroidin or thymidine-kinase sequences
Kongsvik et al. Subfractionation of CsCI-purified H-1 parvovirus on metrizamide gradients
Carlsen et al. An improved method for the isolation of surface membranes from cells in monolayer culture
WO2000068395A3 (en) Sulfohydrolases, corresponding amino acid and nucleotide sequences, sulfohydrolase preparations, processes, and products thereof
WO2023225545A3 (en) Liver de-targeted recombinant aav capsid proteins
Loveday et al. Incorporation of thymine into φe dna during transfection of Bacillus subtilis
Luftig et al. Quantitation of endogenous C-type virion production in several murine cell lines